Mikicort (Budesonide)

Budesonide, the active ingredient in Mikicort, is a glucocorticoid presented as an oral formulation for oral use. It provides anti‑inflammatory activity for conditions of the gastrointestinal tract and other inflammatory disorders. GNH USA supplies Mikicort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mikicort (budesonide) is used in diseases where local anti‑inflammatory action in the gastrointestinal tract is required. - Crohn's disease: induces remission of mild to moderate ileocecal disease. - Ulcerative colitis: helps achieve and maintain remission in mild to moderate colitis. - Eosinophilic esophagitis: reduces eosinophilic inflammation and improves swallowing symptoms.

Budesonide may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth and throat. - Nausea: feeling of sickness or urge to vomit. - Headache: mild to moderate cranial pain. - Abdominal pain: discomfort in the stomach area. - Increased appetite: heightened desire for food. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Severe infections: opportunistic bacterial, viral or fungal infections. - Osteoporosis: loss of bone mineral density leading to fractures. - Hyperglycemia: elevated blood glucose levels, especially in diabetics. - Psychiatric effects: mood swings, depression or psychosis. - Growth retardation in children: impaired linear growth with prolonged therapy.

When prescribing budesonide, clinicians should consider several safety measures. - Assess adrenal function: evaluate cortisol levels before and during therapy. - Monitor blood glucose: check glycemic control in diabetic patients. - Use lowest effective dose: limit exposure to the minimum dose needed for disease control. - Avoid abrupt discontinuation: taper the dose to prevent withdrawal symptoms. - Evaluate bone health: consider calcium and vitamin D supplementation for long‑term use. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Budesonide can interact with other medicines that affect its metabolism or therapeutic effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adrenal suppression. - Systemic immunosuppressants (e.g., azathioprine) at high doses: may amplify immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce budesonide levels and diminish efficacy. - Antacids containing aluminum or magnesium: may affect absorption of oral formulations. - Live vaccines: concurrent use may increase risk of infection due to immunosuppression.